Introduction
============

Nausea and vomiting are common chemotherapy-associated side effects ranked by patients as especially distressing.[@b1-cmar-7-175]--[@b7-cmar-7-175] Chemotherapy-induced nausea and vomiting (CINV) can cause psychological distress, nutritional deficiencies, and reduced quality of life among patients receiving chemotherapy.[@b5-cmar-7-175]--[@b8-cmar-7-175] Furthermore, its occurrence may potentially affect adherence to chemotherapy regimens, leading to treatment delays or receipt of fewer treatments or lower dosages than recommended.[@b9-cmar-7-175],[@b10-cmar-7-175] Such events may have an adverse effect on treatment efficacy, ultimately resulting in suboptimal clinical outcomes and potentially increased health care-related resource utilization and costs.[@b3-cmar-7-175]

Recognizing the importance of preventing and managing CINV, leading oncology societies have issued treatment guidelines[@b11-cmar-7-175]--[@b13-cmar-7-175],[@b29-cmar-7-175] recommending 5-hydroxytryptamine-receptor antagonists (5-HT~3~ RAs) as the preferred medication class to effectively prevent CINV in patients receiving highly emetogenic chemotherapy (HEC) or moderately EC (MEC).[@b19-cmar-7-175],[@b20-cmar-7-175] Compared to the older agents, palonosetron -- a newer 5-HT~3~ RA -- is pharmacologically distinct, with a longer half-life and greater receptor-binding affinity, allosteric binding to serotonin receptors with positive cooperativity, and cross talk with Neurokinin-1 (NK-1) receptors.[@b21-cmar-7-175]--[@b23-cmar-7-175] While the early 5-HT~3~ RA compounds were considered equally efficacious,[@b19-cmar-7-175] palonosetron demonstrated greater efficacy than active comparators in preventing CINV in patients receiving HEC or MEC in multiple clinical trials.[@b20-cmar-7-175],[@b24-cmar-7-175]--[@b26-cmar-7-175] Hatoum et al compared palonosetron with other 5-HT~3~ RAs in a real-world setting among patients with breast/lung cancer undergoing cisplatin/carboplatin treatments.[@b19-cmar-7-175],[@b27-cmar-7-175] They concluded that patients who received prophylaxis with palonosetron had a significantly lower risk of CINV events than those who had received other 5-HT~3~ RA agents. Furthermore, those breast/lung cancer patients receiving palonosetron experienced 49.5% and 29.1% fewer CINV days, respectively.[@b27-cmar-7-175] Their study focused on serious CINV events resulting in hospital or emergency department admissions, and did not include CINV events occurring in an outpatient context. Craver et al found that prophylactic administration of palonosetron among patients with hematologic malignancies who were receiving HEC/MEC resulted in a 20.4% decrease in CINV event rate per cycle compared with patients receiving other 5-HT~3~ RAs.[@b28-cmar-7-175] However, while 5-HT~3~ RA agents have been proven effective in preventing CINV, little is known regarding their impact on chemotherapy treatment adherence and delay. To address these questions, a real-world study was designed comparing patients who received palonosetron with those who received other 5-HT~3~ RAs on incidence of acute and delayed CINV and chemotherapy treatment delay and adherence. This study also contributes to the development of methods to assess medication adherence for intravenous (IV) agents.

Materials and methods
=====================

This was an observational nested case--control study using data from the HealthCore Integrated Research Database (HIRD^SM^). The HIRD is an integrated medical and pharmacy-claims and laboratory-result database of commercially insured patients from 14 major commercial health plans across the US representing approximately 45 million patient-lives dating as far back as January 1, 2001.

Cohort creation
---------------

The index date was defined as the earliest medical or pharmacy claim date for an IV HEC or MEC between January 1, 2002 and October 31, 2010. All patients included in the study were adults (≥18 years of age as of the index date) who had one or more medical claims with a diagnosis of primary malignant breast, lung, or colorectal neoplasm during the baseline period, which was defined as the 12 months before the index date. All patients had continuous medical and pharmacy health plan eligibility for at least 12 months pre- and 12 months postindex date. Patients were excluded if they 1) had a secondary malignant neoplasm or primary neoplasms at multiple sites, 2) had preindex HEC or MEC claims, 3) initiated multiday chemotherapy, 4) received oral chemotherapy alone or in combination with an IV formulation, 5) switched from a single-day-per-cycle chemotherapy regimen to multiday chemotherapy, or 6) had medical claim(s) for pregnancy, labor, or delivery in the 6 months postindex.

Lastly, in order to create clean comparison cohorts, patients receiving both palonosetron and any of the "other" 5-HT~3~ RAs any time during the course of one or more chemotherapy treatment cycles were excluded from the analysis. The remaining patients were stratified into either the palonosetron or other 5-HT~3~ RA treatment cohorts. Specifically, patients in the palonosetron group received only palonosetron and no other IV 5-HT~3~ RA agent (ie, dolasetron, granisetron, and/or ondansetron; see [Table S1](#SD1-cmar-7-175){ref-type="supplementary-material"}) as prophylactic or rescue therapy beginning 1 day before through 5 days after the start of any chemotherapy treatment cycle; those in the other 5-HT~3~ RA cohort were allowed to receive any prophylactic 5-HT~3~ RA agent other than palonosetron.

Assignment of chemotherapy regimens
-----------------------------------

Index HEC and MEC agents were defined as any chemotherapeutic agent classified as having a known high or moderate emetogenic potential ([Table S2](#SD2-cmar-7-175){ref-type="supplementary-material"}).[@b29-cmar-7-175] Chemotherapy agents were identified using generic product identifier (GPI) and Healthcare Common Procedure Coding System (HCPCS) codes. Chemotherapy dose determined the HEC/MEC status of certain chemotherapy drugs (eg, cyclophosphamide and cisplatin) by calculating the index dose administered and then applying the National Comprehensive Cancer Network^®^ (NCCN^®^)-recommended Guidelines available at the time of the study for classification ([Table S3](#SD3-cmar-7-175){ref-type="supplementary-material"}).[@b29-cmar-7-175] Because only single-day administration regimens were included in the study, the average dose was equal to the average strength, as noted on medical or pharmacy claims. Body-surface area (BSA) was not available on claim forms, so published BSA estimates of cancer patients were used to determine the average dose per square meter.[@b30-cmar-7-175] The standard estimates used were 1.91 m^2^ for men (95% confidence interval \[CI\] 1.90--1.92) and 1.71 m^2^ for women (95% CI 1.70--1.72).

For regimens involving a combination of chemotherapeutic agents, the agent with the highest emetic risk defined the risk of the combination (ie, one MEC agent and one HEC agent equaled an HEC regimen; one lowly EC \[LEC\] and one MEC equaled an MEC regimen).[@b12-cmar-7-175],[@b13-cmar-7-175] Two MEC agents were classified as HEC; however, two LEC agents remained a lowly emetogenic regimen ([Table 1](#t1-cmar-7-175){ref-type="table"}).[@b31-cmar-7-175] Additional information on the step-by-step regimen identification can be found in the Supplementary materials.

Claims for index chemotherapy agents dated 7 days or later after the beginning of the cycle were designated as the beginning of the subsequent cycle, and so on until the end of the 12-month observation period. The end of a chemotherapy cycle was determined using either the passing of the NCCN-recommended number of weeks between two cycles ([Table 2](#t2-cmar-7-175){ref-type="table"}), which was specific to each treatment regimen, or the start date of the subsequent treatment cycle, whichever occurred earlier.

Outcome measures
----------------

Acute CINV was identified by *International Classification of Diseases*, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for nausea and vomiting, persistent vomiting, or volume depletion, or current procedural terminology codes for hydration, on the day of chemotherapy ([Table S1](#SD1-cmar-7-175){ref-type="supplementary-material"}). Delayed CINV was identified by the same ICD-9-CM and CPT codes for nausea and vomiting, volume depletion and hydration, as well as GPI/HCPCS codes for IV rescue medications (dexamethasone, fosaprepitant, diphenhydramine, promethazine, haloperidol, prochlorperazine, lorazepam, or metoclopramide) or 5-HT~3~ RAs ([Table S1](#SD1-cmar-7-175){ref-type="supplementary-material"}) between the day after chemotherapy and day 5 of the chemotherapy cycle of interest. CINV events were assessed on a patient- and cycle-level basis.

Each index chemotherapy regimen was assigned a total number of chemotherapy cycles and an allowed gap between chemotherapy cycles according to the recommendations of the 2011 NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines^®^) ([Table 2](#t2-cmar-7-175){ref-type="table"}).[@b14-cmar-7-175]--[@b18-cmar-7-175] For example, a lung cancer patient on cisplatin (index dose of 100 mg/m^2^) and vinorelbine would be assumed to have initiated a therapy involving four treatment cycles with an allowed rest period of 4 weeks between each cycle.

Treatment delay was measured in two ways: 1) the proportion of patients who delayed their index chemotherapy based on the presence of a significant gap between two chemotherapy cycles, and 2) the mean and median time from the index date to the date of treatment delay. Delay of therapy was defined as a gap in treatment exceeding twice the NCCN-specified cycle length specific to each chemotherapy regimen ([Table 2](#t2-cmar-7-175){ref-type="table"}). The date of treatment delay was the date of the last chemotherapy cycle start date prior to delay plus one cycle length. For patients on combination regimens, delay of any one agent involved in the regimen constituted delay of the entire regimen. We also performed a sensitivity analysis around the permissible treatment gap, assigning a lower limit of 1.5 times the NCCN-recommended cycle length and an upper limit of three times the NCCN-recommended cycle length.

Treatment adherence was measured in four related ways: the percentage of patients who received the 1) recommended number of cycles for their specific chemotherapy regimen, as determined by NCCN guidelines, 2) recommended number of chemotherapy cycles for their regimen within the recommended time frame, 3) recommended chemotherapy dose within a 10% margin, and 4) recommended number of cycles within the specified time frame at the expected dose. We used measure 2 as our primary measure of adherence. Patients on multiagent regimes were required to be adherent with each component of the regimen to be considered adherent overall.

Statistical analysis
--------------------

Descriptive statistics were used to characterize the incidence of acute and delayed CINV, as well as baseline patient characteristics, such as primary cancer site and chemotherapy regimen. Means/standard deviations were used for continuous data, and counts/relative frequencies were used for categorical data. Each baseline characteristic and study outcome was compared using unadjusted statistical tests between patients receiving palonosetron and those receiving all other 5-HT~3~ RAs. Continuous variables were compared using Student's *t*-test or Wilcoxon rank-sum test, depending on the distributional characteristics. Categorical data were compared using *χ*^2^ tests.

Logistic regression models were used to estimate associations between antiemetic treatment (palonosetron versus other 5-HT~3~ RAs) and CINV (acute and/or delayed), delay of index chemotherapy regimen, and adherence to index chemotherapy regimen. Covariates in the multivariable regression analysis included age, sex, geographic region, health plan type, year of index date, cancer type, Deyo--Charlson Comorbidity Index (DCI) score,[@b32-cmar-7-175] individual comorbidities, and baseline receipt of LEC, radiation, and antiemetics. All analyses were stratified by HEC and MEC regimens.

Results
=======

Patient characteristics
-----------------------

We identified 1,832 HEC patients who received only palonosetron and no other 5-HT~3~ RA and 2,387 HEC patients who received other 5-HT~3~ RAs excluding palonosetron ([Table 3](#t3-cmar-7-175){ref-type="table"}). In the HEC group, the mean age was slightly higher among palonosetron users (52.0 versus 51.4 years for those receiving other 5-HT~3~ RAs, *P*=0.0345), and breast cancer was the most common malignancy (97.3% palonosetron and 96.0% other 5-HT~3~ RAs). The mean baseline DCI scores were 4.35 for patients receiving palonosetron and 4.56 for those receiving other 5-HT~3~ RAs (*P*=0.0211). Similarly, we identified 1,350 palonosetron users and 1,379 other 5-HT~3~ RA recipients who indexed on an MEC therapy. Within the MEC cohort, the mean age and DCI scores were slightly lower among palonosetron patients compared to those receiving other 5-HT~3~ RAs (56.8 versus 59.2 years, *P*\<0.0001; 4.29 versus 4.55, *P*=0.0229; respectively). Breast (48.6%) and colon (29.3%) cancers were the most prevalent malignancies among palonosetron recipients, whereas lung (35.2%) and colon (34.0%) cancers were more common among those receiving other 5-HT~3~ RAs in the MEC group.

Incidence of CINV
-----------------

Within the HEC cohort, fewer palonosetron patients experienced CINV compared with those who received other 5-HT~3~ RAs (27.5% versus 32.2%, *P*=0.001; [Table 4](#t4-cmar-7-175){ref-type="table"}). Likewise, 19.1% and 14.8% of HEC patients receiving palonosetron experienced ≥1 acute and ≥1 delayed CINV event(s) respectively, compared to 20.5% and 20.2% of other 5-HT~3~ RA HEC patients. Furthermore, patients in the other 5-HT~3~ RA group experienced more CINV events per cycle than the palonosetron group (0.3 versus 0.2 events/cycle). In the MEC cohort, fewer palonosetron patients experienced CINV and CINV events per cycle compared with those who received other 5-HT~3~ RAs (36.1% versus 41.7%, *P*=0.003; 0.3 versus 0.4 events/cycle). MEC patients in the palonosetron cohort were significantly less likely to experience delayed CINV versus patients in the other 5-HT~3~ RA cohort (20.6% versus 29.5%, *P*\<0.0001).

Chemotherapy treatment delay
----------------------------

Fewer chemotherapy treatment delays occurred among patients receiving palonosetron compared with other 5-HT~3~ RAs in both the HEC (3.2% versus 6.0%, *P*\<0.0001) and MEC (17.0% versus 26.8%, *P*\<0.0001) cohorts ([Table 4](#t4-cmar-7-175){ref-type="table"}). The results for delayed therapy remained consistent when using the upper and lower limits as defined earlier (see [Table 4](#t4-cmar-7-175){ref-type="table"}). Mean time to delay was similar across the palonosetron and other 5-HT~3~ RAs groups (approximately 76 days in the HEC cohort and 86 days in the MEC cohort).

Chemotherapy treatment adherence
--------------------------------

In both the HEC and MEC cohorts, more patients receiving palonosetron were adherent to their chemotherapy regimen compared to those who received other 5-HT~3~ RAs for three of the four different adherence measures. In the HEC cohort, slightly more of those who received palonosetron completed the recommended number of chemotherapy cycles versus those who received other 5-HT~3~ RAs (87.7% versus 86.4%, respectively; *P*=0.2022). The difference was greater in the MEC cohort, with 65.6% of those receiving palonosetron and 59.8% of those receiving other 5-HT~3~ RAs completing the recommended number of chemotherapy cycles (*P*=0.0017). Compared with those who received other 5-HT~3~ RAs, significantly more patients receiving palonosetron completed the recommended number of chemotherapy cycles within the specified time frame (HEC, 74.7% versus 69.7%, respectively, *P*=0.0004; MEC, 43.1% versus 37.3%, respectively, *P*=0.0019) and at the expected doses (HEC, 27.3% versus 25.8%, respectively, *P*=0.0004; MEC, 15.0% versus 12.6%, respectively, *P*=0.0019) ([Table 4](#t4-cmar-7-175){ref-type="table"}). A similar proportion of patients in both the palonosetron and other 5-HT~3~ RA cohorts received the recommended chemotherapy doses for HEC (33.6% palonosetron and 33.4% other 5-HT~3~ RAs, *P*=0.8951) and MEC regimens (34.6% palonosetron and 37.1% other 5-HT~3~ RAs, *P*=0.1673).

These findings were supported in a multivariable analysis ([Figure 1](#f1-cmar-7-175){ref-type="fig"}). Treatment with palonosetron was associated with a reduced likelihood of CINV occurrence in the HEC (odds ratio \[OR\] 0.82, 95% CI 0.71--0.95) and MEC (OR 0.77, 95% CI 0.65--0.92) cohorts. Palonosetron treatment was also associated with fewer chemotherapy treatment delays in both cohorts (HEC, OR 0.63, 95% CI, 0.45--0.87; MEC, OR 0.74, 95% CI 0.60--0.91). Although palonosetron was associated with greater chemotherapy adherence in the HEC cohort (OR 1.25, 95% CI 1.07--1.45), no association was found in the MEC cohort (OR 1.1, 95% CI 0.92--1.32).

Discussion
==========

In this retrospective, observational, nested case--control study, patients who received prophylactic or rescue palonosetron had significantly fewer CINV events, fewer chemotherapy treatment delays, and higher adherence to their chemotherapy regimen compared with patients who received any other IV 5-HT~3~ RA medication. These findings were seen both among patients who were undergoing HEC treatment and those undergoing MEC treatment.

Results from clinical trials have demonstrated the overall efficacy of palonosetron in preventing acute CINV in patients receiving HEC and in preventing acute or delayed CINV in patients receiving MEC.[@b20-cmar-7-175],[@b24-cmar-7-175]--[@b26-cmar-7-175] However, limited evidence is available regarding the effect of palonosetron on chemotherapy adherence and treatment delay in a real-world setting. To our knowledge, no previous study has evaluated this association. A previous administrative claims analysis evaluated the risk of serious CINV events associated with hospital or emergency department admissions among patients with breast or lung cancer undergoing MEC or HEC who received palonosetron compared with those who received any other 5-HT~3~ RA.[@b19-cmar-7-175] Patients receiving palonosetron experienced a significantly reduced risk of serious CINV compared to those who received other 5-HT~3~ RAs, ranging from 31% to 45% among lung and breast cancer patients, respectively. Another recent study by Craver et al evaluated the risk of CINV among recipients of palonosetron versus other 5-HT~3~ RAs initiating HEC/MEC therapy in all medical settings,[@b28-cmar-7-175] using a broader definition of CINV encompassing events occurring any time within 7 days of the chemotherapy cycle-start date. While both studies showed a reduction in CINV with palonosetron use as expected, an exploration of the effect of CINV risk reduction on chemotherapy adherence or delay was not conducted.

The real-world analysis in the current study demonstrated improved adherence to chemotherapy regimens among patients who received palonosetron compared with other 5-HT~3~ RA agents. The association between the use of antiemetics and adherence may have been underestimated: patients undergoing chemotherapy, particularly HEC, are more likely to have been prepared by their health care providers to expect nausea and vomiting; such preparedness has been shown to alleviate the reported incidence of nausea and vomiting in patients receiving chemotherapy.[@b31-cmar-7-175] Additionally, some patients undergoing IV chemotherapy regimens will have advanced disease, and may therefore not have the option of delaying or discontinuing treatment because of nausea and vomiting.[@b33-cmar-7-175]

Future research exploring the association between reduced CINV and chemotherapy adherence would benefit from a cost analysis, which was not included in the current study. A therapy that improves chemotherapy adherence by reducing CINV events could potentially reduce costs, both direct (costs of antiemetic medications, physician visits, and hospitalizations) and indirect (lost workdays and intangibles, including lower quality of life and potential consequences of delayed or reduced chemotherapy treatment). Other chemotherapy-associated side effects, such as fatigue, insomnia, or dermatologic conditions, which cannot be easily identified through claims, may also affect treatment adherence.

The nature of the administrative claims database and the lack of granularity precluded us from identifying more than one CINV event per day or the severity of the CINV experienced. While our approach to identify CINV events from claims matches that used in clinical trials of antiemetics,[@b19-cmar-7-175],[@b28-cmar-7-175] others have used criteria that were either more strict (eg, nausea, vomiting, and dehydration associated with hospital admissions[@b27-cmar-7-175]) or that relied on patient diaries rather than diagnosis codes.[@b24-cmar-7-175],[@b25-cmar-7-175] The strategy used in the current study to define CINV did not capture patients using oral antiemetics or over-the-counter remedies, and the IV antiemetics may have been prescribed for reasons other than CINV (eg, for nausea and vomiting associated with migraine,[@b34-cmar-7-175] surgery,[@b35-cmar-7-175] or gastroparesis[@b36-cmar-7-175]). Nausea and vomiting occurring after day 5 of the chemotherapy cycle and before the subsequent cycle were not attributed to chemotherapy, and may have resulted in an underestimation of CINV events. Despite these limitations, the narrow time frame and broader medical setting used for identifying CINV in the current study design resulted in a conservative estimate of the impact of palonosetron and other 5-HT~3~ RAs on CINV in a real-world setting.

Administrative claims are designed for reimbursement rather than research, and may contain coding errors or omissions. Therefore, the claim-based algorithm developed to identify patients with early stage cancers may be susceptible to potential misidentification. Furthermore, standard definitions of adherence with IV chemotherapy regimens within an administrative claim database are lacking in the published literature. All patients were members of large commercial health plans in the US; the results may not be generalizable to patients outside the US or with other types of health insurance. While enrollment was limited to patients with single-day chemotherapy regimens, further research in patients receiving multiday regimens would be desirable. Because of concerns regarding patient selection and cohort size, the comparative analysis was limited to IV chemotherapy in general and IV 5-HT~3~ RAs as a class. Consistent with NCCN guideline recommendations, the analysis assumed that the non-5-HT~3~ RA components of the observed antiemetic regimens were similar across the palonosetron and other cohorts. NCCN guidelines were used to define chemotherapy regimens for this analysis, and did not allow for individualized treatment plans. BSA was needed to calculate the index dosage of cyclophosphamide and cisplatin; however, this information is unavailable in administrative claims. In the absence of US-based data, BSA estimates developed in a prior UK study[@b30-cmar-7-175] were used to calculate index doses.

Conclusion
==========

In this real-world retrospective analysis, patients receiving palonosetron were more adherent to their HEC/MEC regimens and experienced fewer treatment delays compared to patients receiving other 5-HT~3~ RAs. Palonosetron was also associated with a decrease in the occurrence of CINV events. These results highlight the importance of symptom control in the context of adherence to prescribed chemotherapy, which may ultimately influence treatment and disease outcomes, including costs. This study also presents an innovative approach to estimate adherence to IV chemotherapy using administrative claims data.

Supplementary materials
=======================

Assignment of index chemotherapy regimens
-----------------------------------------

Identification of chemotherapeutic regimens involves a two-step process. Step one involves the identification of the highly emetogenic chemotherapy (HEC)/moderately EC (MEC) agents making up the regimen, which are identified within 6 days of the index date. For instance, for a breast cancer patient with a claim for cyclophosphamide on the index date (ie, the start date of the first chemotherapy cycle), medical and pharmacy claims are evaluated to determine the presence of another HEC/MEC drug (eg, doxorubicin, epirubicin, etc). If no other HEC/MEC drug is found, then the index dose is calculated by using the strength (as determined from the index medical or pharmacy claim) and the body surface-area estimate. A dose of \>1,500 mg/m^2^ indicates receipt of HEC, while an index dose ≤1,500 mg/m^2^ indicates MEC. However, if doxorubicin is present, then the patient is classified as HEC as per the Hesketh algorithm.[@b31-cmar-7-175] Step two of the chemotherapy-regimen identification involves claims for non-HEC/MEC chemotherapy agents also observed within 6 days of the index date ([Table S3](#SD3-cmar-7-175){ref-type="supplementary-material"}). In the aforementioned example, for a patient indexing on cyclophosphamide and doxorubicin, if a claim for another lowly EC or non-EC drug (eg, docetaxel, paclitaxel, etc) is found within ±6 days of the index date, then the patient's adherence will be evaluated as per the NCCN Guidelines^®^ recommendations for the appropriate cyclophosphamide/doxorubicin/docetaxel combination regimen. Where multiple regimen options were available for the drugs involved, additional analysis was performed to determine the specific regimen. This included determining the doses of the HEC/MEC components in order to pinpoint the specific regimen. For example, a doxorubicin dose of 50 and 60 mg/m^2^ would indicate a regimen involving six and four cycles, respectively ([Table 2](#t2-cmar-7-175){ref-type="table"}). Duration between the claims for the index HEC/MEC drugs was also used if the doses were insufficient in differentiating among the various regimen options. A combination involving cyclophosphamide/doxorubicin/paclitaxel could be assigned a regimen either 8 weeks or 12 weeks long if the gap between the first and second claim for cyclophosphamide/doxorubicin was found to be 14 or 21 days, respectively.

###### 

CINV codes and antiemetic therapies

  Generic name                                GPI                                                                                                     HCPCS                                      ICD-9-CM diagnosis
  ------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------ --------------------
  **5-HT~3~ RAs**                                                                                                                                                                                
  Dolasetron mesylate                         50250025x                                                                                               J1260, Q0180                               
  Granisetron                                 50250035x                                                                                               J1626, Q0166                               
  Ondansetron                                 50250065x                                                                                               J2405, Q0179                               
  Palonosetron                                50250070x                                                                                               J2469                                      
  **Other antiemetics**                                                                                                                                                                          
  Dexamethasone                               22100020x                                                                                               J1094, J1100, J7637, J7638, J7312, J8540   
  Fosaprepitant                               502800351021x                                                                                           J1453                                      
  Promethazine                                41400020101210, 414000201020x, 414000201003x, 41400020101215, 414000201029x, 414000201052x              J2550, J2180, Q0169, Q0170                 
  Prochlorperazine                            59200055x                                                                                               J0780, Q0164, Q165, S0183                  
  Metoclopramide                              523000201020x, 523000201003x, 523000201012x, 523000201013x, 523000201029x, 523000201072x, 5230002011x   J2765                                      
  Lorazepam                                   571000600020x, 571000600003x, 571000600013x                                                             J2060                                      
  Haloperidol                                 5910001030x, 591000102020x, 5910001010x, 591000102013x                                                  J1630, J1631                               
  Diphenhydramine                             4120003010x, 412000303x, 60300020x, 6030990x                                                            J1200, Q0163                               
  **Nausea**                                                                                                                                                                                     
  Nausea and vomiting                         22100020x                                                                                               J1094, J1100, J7637, J7638, J7312, J8540   787.0x
  Persistent vomiting                         5028002000x                                                                                             J8501                                      536.2x
  Volume depletion                            502800351021x                                                                                           J1453                                      276.5x
  Hydration (nontherapeutic administration)                                                                                                           96360, 96361, 90760, 90761, 2018F, G0345   

**Abbreviations:** CINV, chemotherapy-induced nausea/vomiting; HT, hydroxytryptamine; RAs, receptor antagonists; GPI, generic product identifier; HCPCS, Healthcare Common Procedure Coding System; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification.

###### 

Chemotherapy codes and emetogenic potential

  Description                     GPI code                             HCPCS code                   Emetogenicity   Formulation
  ------------------------------- ------------------------------------ ---------------------------- --------------- -------------
  Carmustine                      21102010x                            J9050, C9437                 Other           IV
  Cisplatin                       211000200020x                        J9060, J9062, C9418          Other           IV
  Dacarbazine                     2170002000x                          J9130, J9140, C9423          HEC             IV
  Mechlorethamine                 211010301021x                        J9230                        HEC             IV
  Streptozotocin                  21102030002105                       J9320                        HEC             IV
  Alemtuzumab                     21353010x                            J9010                        Minimal         IV
  Arsenic trioxide                21700008x                            J9017                        MEC             IV
  Azacitidine                     21300003x                            J9025                        MEC             IV
  Bendamustine                    21100009x                            J9033                        MEC             IV
  Carboplatin                     21100015x                            J9045                        MEC             IV
  Clofarabine                     21300008x                            J9027, C9129                 MEC             IV
  Dactinomycin                    212000200021x                        J9120                        MEC             IV
  Daunorubicin                    21200030x                            J9150--J9151, C9424          MEC             IV
  Doxorubicin                     21200040x                            J9000--J9001, C9415          Other           IV
  Epirubicin                      21200042x                            J9178, J9180                 Other           IV
  Idarubicin                      21200045x                            J9211, C9429                 MEC             IV
  Ifosfamide                      2110102500x, 219900024064x           J9208, C9427                 Other           IV
  Irinotecan                      21550040x                            J9206                        MEC             IV
  Melphalan                       211010400021x, 211010401021x         J9245                        MEC             IV
  Oxaliplatin                     21100028x                            J9263, C9205                 MEC             IV
  Temozolomide                    211040700021x                        J9328, C9253                 MEC             IV
  Aldesleukin                     21703020x                            J9015                        Other           IV
  Amifostine crystalline          21758010x                            J0207                        Other           IV
  Cyclophosphamide                21101020002x                         J9070--J9097, C9420, C9421   Other           IV
  Cytarabine                      21300010x                            J9098--J9110, C9422          Other           IV
  Interferon-α                    217000601x, 217000602x, 217000603x   J9212--J9215                 Other           IV
  Altretamine                     21100005x                                                         MEC/HEC         Oral
  Procarbazine                    21700050x                            S0182                        MEC/HEC         Oral
  Cyclophosphamide                211010200003x                        J8530                        Other           Oral
  Imatinib                        21534035x                            S0088                        Minimal/Low     Oral
  Temozolomide                    211040700001x                        J8700                        Other           Oral
  Busulfan                        211000100003x                        J0594, J8510                 Other           Oral
  Estramustine phosphate sodium   2140302010x                                                       MEC/HEC         Oral
  Etoposide                       21500010x                            J8560                        MEC/HEC         Oral
  Lomustine                       211020200001x                        S0178                        MEC/HEC         Oral

**Notes:** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®^) for Antiemesis, Version 1.2012. © National Comprehensive Cancer Network, Inc 2015. All rights reserved. Accessed August 11, 2011. To view the most recent and complete version of the guideline, go online to [NCCN.org](http://NCCN.org). NATIONAL COMPREHENSIVE CANCER NETWORK^®^, NCCN^®^, NCCN GUIDELINES^®^, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Other = NCCN emetogenicity rating depends on dosage.

**Abbreviations:** GPI, generic product identifier; HCPCS, Healthcare Common Procedure Coding System; HEC, highly EC; MEC, moderately EC; EC, emetogenic chemotherapy; IV, intravenous.

###### 

HEC/MEC regimens

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agent                                      Regimen                                                Schedule                                      Regimen type            MEC/HEC
  ------------------------------------------ ------------------------------------------------------ --------------------------------------------- ----------------------- -----------------------
  Cyclophosphamide                           TC                                                     • Cyclophosphamide 600 mg/m^2^ IV day 1\      Single day              Depends on dosage
                                                                                                    Cycled every 3 weeks for four cycles                                  

  Cyclophosphamide/doxorubicin               TAC (with docetaxel)                                   • Doxorubicin 50 mg/m^2^ IV day 1             Single day              HEC

  • Cyclophosphamide 500 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for six cycles                                                                                                                                     

  TAC (with docetaxel)                       • Doxorubicin 60 mg/m^2^ on day 1                      Single day                                    HEC                     

  • Cyclophosphamide 500 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for four cycles                                                                                                                                    

  AC                                         • Doxorubicin 60 mg/m^2^ IV day 1                      Single day                                    HEC                     

  • Cyclophosphamide 600 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 2 weeks for four cycles                                                                                                                                    

  • Doxorubicin 60 mg/m^2^ IV day 1          Single day                                             HEC                                                                   

  • Cyclophosphamide 600 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for four cycles                                                                                                                                    

  • Doxorubicin 60 mg/m^2^ IV day 1          Single day                                             HEC                                                                   

  • Cyclophosphamide 600 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for four cycles                                                                                                                                    

  • Doxorubicin 60 mg/m^2^ IV day 1          Single day                                             HEC                                                                   

  • Cyclophosphamide 600 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for four cycles                                                                                                                                    

  FAC/CAF (with 5-FU)                        • Doxorubicin 50 mg/m^2^ IV day 1                      Single day                                    HEC                     

  • Cyclophosphamide 500 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for six cycles                                                                                                                                     

  Cyclophosphamide/epirubicin                FEC/CEF (with 5-FU)                                    • Epirubicin 75 mg/m^2^ IV day 1              Single day              HEC

  • Cyclophosphamide 500 mg/m^2^ day 1\                                                                                                                                   
  Cycled every 3 weeks for four cycles                                                                                                                                    

  EC                                         • Epirubicin 100 mg/m^2^ IV day 1                      Single day                                    HEC                     

  • Cyclophosphamide 830 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for eight cycles                                                                                                                                   

  FEC                                        • Epirubicin 100 mg/m^2^ IV day 1                      Single day                                    HEC                     

  • Cyclophosphamide 500 mg/m^2^ day 1\                                                                                                                                   
  Cycled every 3 weeks for three cycles                                                                                                                                   

  FEC                                        • Epirubicin 90 mg/m^2^ IV day 1                       Single day                                    HEC                     

  • Cyclophosphamide 600 mg/m^2^ IV day 1\                                                                                                                                
  Cycled every 3 weeks for four cycles                                                                                                                                    

  Carboplatin                                TCH                                                    • Carboplatin AUC 6 IV day 1\                 Single day              MEC
                                                                                                    Cycled every 3 weeks for six cycles                                   

  CH (with trastuzumab)                      • Carboplatin AUC 6 IV day 1\                          Single day                                    MEC                     
                                             Cycled every 3 weeks for six cycles                                                                                          

  CT (with docetaxel)                        • Carboplatin AUC 6 IV day 1\                          Single day                                    MEC                     
                                             Cycled every 3 weeks for six cycles                                                                                          

  Cisplatin                                  CV (with vinorelbine)                                  • Cisplatin 100 mg/m^2^ day 1\                Single day              HEC/depends on dosage
                                                                                                    Cycled every 4 weeks for four cycles                                  

  CV (with vinorelbine)                      • Cisplatin 75--80 mg/m^2^ day 1\                      Single day                                    HEC/depends on dosage   
                                             Cycled every 3 weeks for four cycles                                                                                         

  CG (with gemcitabine)                      • Cisplatin 75 mg/m^2^ day 1\                          Single day                                    HEC/depends on dosage   
                                             Cycled every 3 weeks for four to six cycles                                                                                  

  CD (with docetaxel)                        • Cisplatin 75 mg/m^2^ day 1\                          Single day                                    HEC/depends on dosage   
                                             Cycled every 3 weeks for four to six cycles                                                                                  

  CP (with pemetrexed)                       • Cisplatin 75 mg/m^2^ day 1\                          Single day                                    HEC/depends on dosage   
                                             Cycled every 3 weeks for four cycles                                                                                         

  Carboplatin                                PC (with paclitaxel)                                   • Carboplatin AUC 6 day 1\                    Single day              MEC
                                                                                                    Cycled every 3 weeks for four to six cycles                           

  PC (with paclitaxel)                       • Carboplatin AUC 2 (initial) and 6 (last 2) weekly\   Single day                                    MEC                     
                                             Total of three cycles                                                                                                        

  PG (with gemcitabine)                      • Carboplatin AUC 2 day 1\                             Single day                                    MEC                     
                                             Cycled every 3 weeks for six cycles                                                                                          

  PE (with etoposide)                        • Carboplatin AUC 2 day 1\                             Single day                                    MEC                     
                                             Cycled every 4 weeks for six cycles                                                                                          

  Oxaliplatin                                FOLFOX                                                 • Oxaliplatin 85 mg/m^2^ day 1\               Single day              MEC
                                                                                                    Cycled every 2 weeks for 6 months                                     

  FOLFOX (modified)                          • Oxaliplatin 85 mg/m^2^ day 1\                        Single day                                    MEC                     
                                             Cycled every 2 weeks for 6 months                                                                                            

  XELOX                                      • Oxaliplatin 130 mg/m^2^ day 1\                       Single day                                    MEC                     
                                             Cycled every 3 weeks for eight cycles                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®^) for Breast Cancer V2.2011, Colon Cancer V3.2011, Rectal Cancer V4.2011, Small Cell Lung Cancer V2.2012, Non-Small Cell Lung Cancer V3.2011 \[All accessed July 11, 2011\], Antiemesis V1.2012 \[Accessed August 11, 2011\]. © National Comprehensive Cancer Network, Inc 2015. All rights reserved. To view the most recent and complete version of the guidelines, go online to [NCCN.org](http://NCCN.org). NATIONAL COMPREHENSIVE CANCER NETWORK^®^, NCCN^®^, NCCN GUIDELINES^®^, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

**Abbreviations:** MEC, moderately emetogenic chemotherapy; HEC, highly EC; TC, taxotere/cyclophosphamide; IV, intravenous; TAC, Docetaxel/doxorubicin/cyclophosphomide; AC, Doxorubicin/cyclophosphomide; FAC/CAF, Flurouracil/doxorubicin/cyclophosphomide; 5-FU, 5-fluorouracil; FEC/CEF, Cyclophosphomide/Epirubicin/Flurouracil; TCH, Docetaxel/carboplatin/trastuzumab; CH, Docetaxel/carboplatin/trastuzumab; CT, Carboplatin/trastuzumab; CV, Cisplatin/vinorelbine; CG, Cisplatin/gemicitabine; CD, Cisplatin/docetaxel; CP, Cisplatin/pemetrexed; PC, Paclitaxel/Carboplatin; PG, Paclitaxel/Carboplatin/gemicitabine; PE, Paclitaxel/Carboplatin/etoposide; FOLFOX, Folinic acid/Fluorouracil/Oxaliplatin; XELOX, Capecitabine/Oxaliplatin.

The authors acknowledge Russell Knoth of Eisai Pharmaceuticals, Inc., for his input on the study design and manuscript. The authors also acknowledge Cheryl Jones for her editorial assistance in preparing the manuscript. Funding for this study was provided by Eisai, Inc., which distributes palonosetron.
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![Odds ratios and 95% confidence intervals for palonosetron versus other 5-HT[@b3-cmar-7-175]-RAs.\
**Notes:** For CINV and delayed therapy, an odds ratio \<1 is associated with improved outcomes; for adherence, an odds ratio \<1 is associated with improved outcomes.\
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###### 

Algorithm to identify HEC and MEC regimens

  Regimen makeup                                                              HEC/MEC classification of regimen
  --------------------------------------------------------------------------- -----------------------------------
  Any HEC drug                                                                HEC
  Two or more MEC drugs                                                       HEC
  One MEC drug with or without low or minimal emetogenic chemotherapy (LEC)   MEC
  Multiple LEC drugs                                                          LEC

**Abbreviations:** HEC, highly emetogenic chemotherapy; MEC, moderately EC; LEC, lowly EC; EC, emetogenic chemotherapy.

###### 

Chemotherapy index regimens

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Index HEC/MEC regimen (± LEC)                                                          Emetogenicity                                                                        Number of recommended cycles[a](#tfn2-cmar-7-175){ref-type="table-fn"}   Allowed gap (weeks)[b](#tfn3-cmar-7-175){ref-type="table-fn"}   Regimen duration (weeks)
  -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------ --------------------------------------------------------------- --------------------------
  **Breast cancer**                                                                                                                                                                                                                                                                                                    

  Cyclophosphamide (600 mg/m^2^; with or without docetaxel)                              If index dose \>1,500 mg/m^2^ then HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"};\   4                                                                        3                                                               12
                                                                                         if index dose ≤1,500 mg/m^2^ then MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                                                                                                                               

  Cyclophosphamide (600 mg/m^2^)/doxorubicin (60 mg/m^2^)                                HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        3                                                               12

  Cyclophosphamide (600 mg/m^2^)/doxorubicin (50 mg/m^2^) + docetaxel                    HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Cyclophosphamide (600 mg/m^2^)/doxorubicin (60 mg/m^2^) + docetaxel                    HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        3                                                               12

  Cyclophosphamide (600 mg/m^2^)/doxorubicin (60 mg/m^2^) + paclitaxel (R^1^)            HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        2                                                               8

  Cyclophosphamide (600 mg/m^2^)/doxorubicin (60 mg/m^2^) + paclitaxel (R^2^)            HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        3                                                               12

  Cyclophosphamide (500 mg/m^2^)/doxorubicin (50 mg/m^2^) + 5-fluorouracil               HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Cyclophosphamide (100 mg/m^2^)/epirubicin (830 mg/m^2^)                                HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        8                                                                        3                                                               24

  Cyclophosphamide (500 mg/m^2^)/epirubicin (75 mg/m^2^) + 5-fluorouracil                HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        3                                                               12

  Cyclophosphamide (500 mg/m^2^)/epirubicin (100 mg/m^2^) + docetaxel + 5-fluorouracil   HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Cyclophosphamide (600 mg/m^2^)/epirubicin (90 mg/m^2^) + paclitaxel + 5-fluorouracil   HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        4                                                                        3                                                               12

  Carboplatin (500--900 mg/m^2^; with docetaxel or trastuzumab or both)                  MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Carboplatin (150 mg) + paclitaxel                                                      MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        3                                                                        1                                                               3

  Carboplatin (500 mg) + paclitaxel                                                      MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        3                                                                        3                                                               9

  Carboplatin (150--900 mg/m^2^) + gemcitabine                                           MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  **Lung cancer**                                                                                                                                                                                                                                                                                                      

  Cisplatin (100 mg) + vinorelbine\                                                      If index dose ≥50 mg/m^2^,\                                                          4\                                                                       4\                                                              16\
  Cisplatin (75--80 mg) + vinorelbine\                                                   then HEC[c](#tfn4-cmar-7-175){ref-type="table-fn"};\                                 4\                                                                       3\                                                              12\
  Cisplatin (75 mg/m^2^) + gemcitabine\                                                  if index dose \<50 mg/m^2^,\                                                         4\                                                                       3\                                                              12\
  Cisplatin (75 mg/m^2^) + docetaxel                                                     then MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                   4                                                                        3                                                               12

  Cisplatin (75 mg/m^2^) + etoposide                                                                                                                                          4                                                                        4                                                               16

  Cisplatin (75 mg/m^2^) + pemetrexed                                                                                                                                         4                                                                        3                                                               12

  Carboplatin (150--900 mg/m^2^) + etoposide                                             MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        4                                                               24

  Carboplatin (150--900 mg/m^2^) + gemcitabine                                           MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Carboplatin (500--900 mg/m^2^) + docetaxel                                             MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        6                                                                        3                                                               18

  Carboplatin (500--900 mg) + paclitaxel                                                 MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        3                                                                        3                                                               9

  Carboplatin (150--900 mg) + paclitaxel                                                 MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        3                                                                        1                                                               3

  **Colorectal cancer**                                                                                                                                                                                                                                                                                                

  Oxaliplatin (85 mg/m^2^) + 5-fluorouracil                                              MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        12                                                                       2                                                               24

  Oxaliplatin (85 mg/m^2^) + 5-fluorouracil + leucovorin                                 MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        12                                                                       2                                                               24

  Oxaliplatin (130 mg/m^2^) + capecitabine                                               MEC[c](#tfn4-cmar-7-175){ref-type="table-fn"}                                        8                                                                        3                                                               24
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

As per NCCN guidelines at the time of the study[@b14-cmar-7-175]--[@b18-cmar-7-175] (the most recent NCCN guidelines indicate minor changes to the emetogenicity classification);

equal to the recommended cycle length as per NCCN guidelines[@b14-cmar-7-175]--[@b18-cmar-7-175];

Hesketh rule in effect.[@b31-cmar-7-175] Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®^) for Breast Cancer V2.2011, Colon Cancer V3.2011, Rectal Cancer V4.2011, Small Cell Lung Cancer V2.2012, Non-Small Cell Lung Cancer V3.2011. © National Comprehensive Cancer Network, Inc 2015. All rights reserved. All accessed July 11, 2011. To view the most recent and complete version of the guidelines, go online to [NCCN.org](http://NCCN.org). NATIONAL COMPREHENSIVE CANCER NETWORK^®^, NCCN^®^, NCCN GUIDELINES^®^, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

**Abbreviations:** HEC, highly emetogenic chemotherapy; MEC, moderately EC; LEC, lowly EC; EC, emetogenic chemotherapy; NCCN, National Comprehensive Cancer Network.

###### 

Palonosetron versus other 5-HT~3~ RAs among patients initiating an HEC/MEC regimen

  Characteristics                                                 HEC                      MEC                                                                       
  --------------------------------------------------------------- ------------------------ -------------------- ---------- -------------------- -------------------- ----------
  Female, n (%)                                                   1,805 (98.5)             2,333 (97.7)         0.0643     981 (72.7)           857 (62.2)           \<0.0001
  Age at index (years), mean ± SD                                 52.04 (±9.52)            51.41 (±9.6)         0.0345     56.82 (±10.9)        59.21 (±11.33)       \<0.0001
   18--44                                                         394 (21.5)               571 (23.9)           0.1046     175 (13.0)           144 (10.4)           \<0.0001
   45--64                                                         1,276 (69.7)             1,632 (68.4)                    858 (63.6)           804 (58.3)           
   ≥65                                                            162 (8.8)                184 (7.7)                       317 (23.5)           431 (31.3)           
  Geographic region, n (%)                                                                                                                                           
   Northeast                                                      288 (15.7)               278 (11.7)           \<0.0001   185 (13.7)           173 (12.6)           \<0.0001
   South                                                          585 (31.9)               736 (30.8)                      445 (33.0)           480 (34.8)           
   Midwest                                                        651 (35.5)               488 (20.4)                      485 (35.9)           406 (29.4)           
   West                                                           232 (12.7)               773 (32.4)                      172 (12.7)           276 (20.0)           
   Unknown                                                        76 (4.2)                 112 (4.7)                       63 (4.7)             44 (3.2)             
  Health plan type, n (%)                                                                                                                                            
   HMO                                                            314 (17.1)               487 (20.4)           0.0047     238 (17.6)           278 (20.2)           0.0115
   POS                                                            99 (5.4)                 85 (3.6)                        49 (3.6)             34 (2.5)             
   PPO                                                            1,286 (70.2)             1,661 (69.6)                    898 (66.5)           879 (63.7)           
   FFS                                                            12 (0.7)                 15 (0.6)                        7 (0.5)              21 (1.5)             
   Other/unknown                                                  121 (6.6)                139 (5.8)                       158 (11.7)           167 (12.1)           
   Medicare plan[c](#tfn8-cmar-7-175){ref-type="table-fn"}        134 (7.3)                190 (8.0)            0.4352     233 (17.3)           353 (25.6)           \<0.0001
  Index year, n (%)                                                                                                                                                  
   2002--2004                                                     16 (0.9)                 736 (30.8)           \<0.0001   8 (0.6)              105 (7.6)            \<0.0001
   2005--2006                                                     936 (51.1)               924 (38.7)                      343 (25.4)           515 (37.4)           
   2007--2008                                                     854 (46.6)               670 (28.1)                      963 (71.3)           685 (49.7)           
   2009--2011                                                     26 (1.4)                 57 (2.4)                        36 (2.7)             74 (5.4)             
  Baseline medical conditions, n (%)                                                                                                                                 
   Breast cancer                                                  1,782 (97.3)             2,291 (96.0)         0.0228     656 (48.6)           425 (30.8)           \<0.0001
   Lung cancer                                                    50 (2.7)                 96 (4.0)             0.0228     299 (22.2)           485 (35.2)           \<0.0001
   Colorectal cancer                                              0                        0                    NA         395 (29.26)          469 (34.0)           0.0076
   Hypertension                                                   679 (37.1)               871 (36.5)           0.7015     700 (51.9)           751 (54.5)           0.1722
   Cerebrovascular disease                                        33 (1.8)                 47 (2.0)             0.6922     80 (5.9)             101 (7.3)            0.1422
   Heart failure                                                  26 (1.4)                 39 (1.6)             0.5748     49 (3.6)             76 (5.5)             0.0187
  Renal disease[d](#tfn9-cmar-7-175){ref-type="table-fn"}         35 (1.9)                 46 (1.9)             0.9689     60 (4.4)             63 (4.6)             0.8759
   Liver disease                                                  28 (1.5)                 34 (1.4)             0.7808     40 (3.0)             36 (2.6)             0.5759
   Diabetes mellitus                                              174 (9.5)                194 (8.1)            0.1179     216 (16)             226 (16.4)           0.7829
   Ischemic heart disease                                         84 (4.6)                 107 (4.5)            0.8738     165 (12.2)           238 (17.3)           0.0002
   Pulmonary disease[e](#tfn10-cmar-7-175){ref-type="table-fn"}   211 (11.5)               297 (12.4)           0.3602     315 (23.3)           460 (33.4)           \<0.0001
   Osteoporosis                                                   197 (10.8)               244 (10.2)           0.5761     149 (11.0)           149 (10.8)           0.8459
   Mental health disorder                                         441 (24.1)               543 (22.8)           0.3135     352 (26.1)           375 (27.2)           0.5083
  DCI score                                                                                                                                                          
   Mean ± SD                                                      4.35 (±2.92)             4.56 (±2.98)         0.0211     4.29 (±2.88)         4.55 (±2.95)         0.0229
   Median (Q1--Q3)                                                2 (2--8)                 3 (2--8)             0.0264     3 (2--8)             3 (2--8)             0.0002
  Baseline therapies, n (%)                                                                                                                                          
   LEC                                                            93 (5.1)                 108 (4.5)            0.4042     193 (14.3)           205 (14.9)           0.6734
   Radiation                                                      60 (3.3)                 113 (4.7)            0.0179     237 (17.6)           290 (21.0)           0.0215
   5-HT~3~ antiemetics                                            675 (36.8)               895 (37.5)           0.6652     450 (33.3)           374 (27.1)           0.0004
   Non-5-HT~3~ antiemetics                                        1,166 (63.7)             1,359 (56.9)         \<0.0001   828 (61.3)           728 (52.8)           \<0.0001
  Chemotherapeutic regimens, n (%)                                                                                                                                   
   Cyclophosphamide                                               6 (0.3)                  7 (0.3)                         499 (37.0)           287 (20.8)           
   Cyclophosphamide/doxorubicin                                   1,656 (90.4)             2,133 (89.4)                                                              
   Cyclophosphamide/epirubicin                                    120 (6.6)                151 (6.3)                                                                 
   Cisplatin                                                      50 (2.7)                 96 (4.0)                        21 (1.6)             13 (0.9)             
   Carboplatin                                                                                                             435 (32.2)           610 (44.2)           
   Oxaliplatin                                                                                                             395 (29.3)           469 (34.0)           
  Duration of study follow-up, days                                                                                                                                  
   Mean ± SD                                                      1,239.79 (±521.83)       1,398.59 (±722.88)   \<0.0001   1,036.1 (±414.11)    1,089.16 (±517.92)   0.0031
   Median (Q1--Q3)                                                1,200 (835.5--1,648.5)   1,295 (807--1,885)   \<0.0001   994.5 (716--1,270)   1,013 (648--1,407)   0.1939

**Notes:**

Receipt of palonosetron and no other 5-HT~3~ RA during any cycle, measured from (HEC cycle-start date -1 day) until (HEC cycle-start date +5 days);

receipt of any 5-HT~3~ RA except palonosetron during any cycle, measured from (chemotherapy cycle-start date -1 day) until (chemotherapy cycle start date +5 days);

consisting of Medicare Advantage, supplemental, and Part D plans;

renal disease included kidney disease, nephrosis, nephritis, and renal function impairment, including dialysis;

pulmonary disease included asthma, bronchitis, pneumonia, emphysema, and COPD.

**Abbreviations:** HT, hydroxytryptamine; RAs, receptor antagonists; HEC, highly EC; MEC, moderately EC; LEC, lowly EC; NEC, non-EC; EC, emetogenic chemotherapy; SD, standard deviation; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; FFS, fee for service; NA, not applicable; Q, quartile; COPD, chronic obstructive pulmonary disease; DCI, Deyo--Charlson Comorbidity Index.

###### 

Outcomes among palonosetron versus other 5-HT~3~ RAs in patients initiating an HEC/MEC regimen

  Outcomes of interest                                                                    HEC              MEC                                                           
  --------------------------------------------------------------------------------------- ---------------- ---------------- ---------- ---------------- ---------------- ----------
  CINV                                                                                                                                                                   
   Patients experiencing ≥1 CINV event, n (%)                                             504 (27.5)       768 (32.2)       0.0011     487 (36.1)       575 (41.7)       0.0026
   Patients experiencing ≥1 acute CINV event                                              350 (19.1)       490 (20.53)      0.2513     361 (26.74)      334 (24.22)      0.1308
   Patients experiencing ≥1 delayed CINV event                                            271 (14.79)      482 (20.19)      \<0.0001   278 (20.59)      407 (29.51)      \<0.0001
   Total number of cycles                                                                 7,616            9,878                       7,952            8,749            
   Total number of events                                                                 1,552            2,685                       2,070            3,686            
   Acute                                                                                  769              1,212                       1,193            1,196            
   Delayed                                                                                783              1,473                       877              2,490            
   Events/cycle                                                                           0.2038           0.2718                      0.2603           0.4213           
  Treatment delay                                                                                                                                                        
   Treatment delay, n (%)                                                                 59 (3.2)         144 (6.0)        \<0.0001   230 (17.0)       369 (26.8)       \<0.0001
   Treatment delay, lower limit, n (%)                                                    102 (5.6)        199 (8.3)        0.0005     363 (26.9)       536 (38.9)       \<0.0001
   Treatment delay, upper limit, n (%)                                                    19 (1.0)         40 (1.7)         0.08       101 (7.5)        163 (11.8)       0.0001
  Therapy length until delay (days)                                                                                                                                      
   Mean (± SD)                                                                            76.28 (±22.65)   76.32 (±22.62)   0.9577     87.38 (±42.45)   85.45 (±48.18)   0.2659
   Median (Q1--Q3)                                                                        67 (64--85)      76 (64--85)      0.0147     85 (62--111)     85 (48--126)     0.0147
  Treatment adherence, n(%)                                                                                                                                              
   Receipt of                                                                                                                                                            
   1. Recommended number of cycles                                                        1,607 (87.7)     2,062 (86.4)     0.2022     885 (65.6)       824 (59.8)       0.0017
   2. Recommended number of cycles within the specified time frame                        1,368 (74.7)     1,664 (69.7)     0.0004     582 (43.1)       514 (37.3)       0.0019
   3. Recommended number of cycles within the specified time frame at the expected dose   500 (27.3)       616 (25.8)       0.0004     202 (15.0)       173 (12.6)       0.0019
   4. Recommended dose                                                                    616 (33.6)       798 (33.4)       0.8951     467 (34.6)       512 (37.1)       0.1673

**Abbreviations:** HT, hydroxytryptamine; RAs, receptor antagonists; HEC, highly EC; MEC, moderately EC; EC, emetogenic chemotherapy; CINV, chemotherapy-induced nausea/vomiting; SD, standard deviation; Q, quartile.
